Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

[1]  V. Beral.  Ovarian cancer and hormone replacement therapy in the Million Women Study , 2007, The Lancet.

[2]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[3]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[4]  O. Olopade,et al.  The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.

[5]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Markman,et al.  Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. , 2004, Gynecologic oncology.

[7]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[8]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[9]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[10]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[11]  J. Simpson,et al.  Ovarian histopathology in breast cancer patients receiving tamoxifen. , 1999, Gynecologic oncology.

[12]  J. Barrett,et al.  BG-1 ovarian cell line: An alternative model for examining estrogen-dependent growth in vitro , 1998, In Vitro Cellular & Developmental Biology - Animal.

[13]  K. Hatch,et al.  Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.

[14]  H. Rochefort,et al.  Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  N. Weiss,et al.  Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. , 1995, Journal of the National Cancer Institute.

[16]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[17]  K. Hatch,et al.  Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patients , 1991, Cancer.

[18]  B. Slotman,et al.  Endocrine factors in common epithelial ovarian cancer. , 1991, Endocrine reviews.

[19]  J. Davis,et al.  Tamoxifen therapy in recurrent epithelial ovarian carcinoma. , 1987, Gynecologic oncology.

[20]  F. Tas,et al.  The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer , 2007, Medical oncology.

[21]  P. Møller,et al.  The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. , 2007, Gynecologic oncology.

[22]  S. Narod,et al.  The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation , 2005, Familial Cancer.

[23]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[24]  A. Figer,et al.  Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. , 1996, Gynecologic oncology.

[25]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.